These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


189 related items for PubMed ID: 21637969

  • 1. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
    Ando K, Haneda M, Ito S, Kashihara N, Node K, Nangaku M, Shimosawa T, Kishimoto J, Fujita T.
    Cardiovasc Drugs Ther; 2011 Aug; 25(4):341-7. PubMed ID: 21637969
    [Abstract] [Full Text] [Related]

  • 2. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 3. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M, Okubo S, Mizubayashi R, Isaka N, Machida H, Okamoto S, Hirota H, Takeuchi M, Kato T, Nakatani K, Mizuno O, Miyagawa K, Makino K, Okura T, Dohi Y, Ito M, Kimura G.
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [Abstract] [Full Text] [Related]

  • 4. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Matsuoka H, Ando K, Ueshima K, Babazono T, Kario K, Tanaka S, Nakao K, Fujita T, SAKURA Trial Investigators.
    Clin Exp Hypertens; 2011 Jul; 33(7):455-62. PubMed ID: 21649534
    [Abstract] [Full Text] [Related]

  • 5. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K, Dohi Y, Nakazawa A, Sugiura T, Yamashita S, Sato K, Kimura G.
    Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
    [Abstract] [Full Text] [Related]

  • 6. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H, Kikuchi F, Ishida T.
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [Abstract] [Full Text] [Related]

  • 7. Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial.
    Takami T, Saito Y.
    Drug Des Devel Ther; 2013 Oct; 7():175-83. PubMed ID: 23662047
    [Abstract] [Full Text] [Related]

  • 8. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S, Mori T, Nako K, Ito S.
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
    Ando K, Ueshima K, Tanaka S, Kosugi S, Sato T, Matsuoka H, Nakao K, Fujita T.
    Int J Med Sci; 2013 Jun; 10(9):1209-16. PubMed ID: 23935398
    [Abstract] [Full Text] [Related]

  • 10. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 11. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M.
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [Abstract] [Full Text] [Related]

  • 12. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K, Ogihara T, Saruta T, Kuramoto K, REZALT Study Group.
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [Abstract] [Full Text] [Related]

  • 13. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
    Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Fukuda T, Numao T, Shimada K, Kario K.
    J Cardiovasc Pharmacol; 2007 Jun; 49(6):394-400. PubMed ID: 17577104
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [Abstract] [Full Text] [Related]

  • 15. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
    Maeda A, Tamura K, Kanaoka T, Ohsawa M, Haku S, Azushima K, Dejima T, Wakui H, Yanagi M, Okano Y, Fujikawa T, Toya Y, Mizushima S, Tochikubo O, Umemura S.
    Clin Exp Hypertens; 2012 Nov; 34(4):249-57. PubMed ID: 22571446
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 17. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
    Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K, ATTEST Study Group.
    Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
    [Abstract] [Full Text] [Related]

  • 18. Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
    Takami T, Saito Y.
    Vasc Health Risk Manag; 2011 Aug; 7():383-90. PubMed ID: 21796252
    [Abstract] [Full Text] [Related]

  • 19. Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Fukumoto S, Ishimura E, Motoyama K, Morioka T, Kimoto E, Wakikawa K, Shoji S, Koyama H, Shoji T, Emoto M, Nishizawa Y, Inaba M, Cilnidipine vs L-type calcium channel blockers Evaluation of Antihypertensive Renoprotective Effects in Diabetic patients (CLEARED) Study Investigators.
    Diabetes Res Clin Pract; 2012 Jul; 97(1):91-8. PubMed ID: 22336632
    [Abstract] [Full Text] [Related]

  • 20. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T, Sato A, Hayashi K, Saruta T.
    Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.